Navigation Links
Hospira Reports Third-Quarter 2012 Results
Date:11/7/2012

y and

product-related matters (mid-point of an

estimated range of $0.78 to $0.88 per diluted share)$(0.83)Estimated charges related to capacity expansion

(mid-point of an estimated range of $0.07 to $0.09

per diluted share)

$(0.08)Estimated charges related to facilities optimization

(mid-point of an estimated range of $0.08 to $0.10

per diluted share)

$(0.09)Estimated charges for other restructuring

$(0.07)Charges related to impairment of certain assets

$(0.09)Projected diluted earnings per share -- GAAP

$0.53The adjusting items are shown net of tax in aggregate of $131 million, which is calculated for the specified adjustments stated above, based on the statutory tax rates in the various tax jurisdictions in which the items are expected to occur.

The company is narrowing the projected range for cash flow from operations in 2012 to between $475 million and $500 million. The company continues to project that depreciation and amortization will range between $240 million and $260 million. Capital expenditures are now projected to range between $325 million and $350 million.

*Use of Non-GAAP Financial MeasuresAdjusted measures used in this press release are reconciled to the most comparable measures calculated in accordance with GAAP in the schedules attached to this release. For more information regarding these non-GAAP financial measures, please see Hospira's Current Report on Form 8-K furnished to the Securities and Exchange Commission on the date of this press release.

Webcast / Complementary MaterialHospira will hold a conference call for investors and media at 8 a.m. Central time on Wednesday, Nov. 7, 2012. A live webcast of the conference call will be available on Hospira's website at www.hospirainvestor.com. Listeners should log on approximately 10
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... PHILADELPHIA, Jan. 20, 2011 The U.S. Food ... System Drugs Advisory Committee decided today that it ... this time based on the currently available data ... of Amyvid conditional on a reader training program ...
... Inc. (Nasdaq: ELGX ), developer of minimally invasive ... release of its fourth quarter and full year 2010 financial ... after the close of the market. Endologix will ... 5:00 p.m. ET / 2:00 p.m. PT to discuss the ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Endologix to Report Fourth Quarter and Full Year 2010 Financial Results on February 22, 2011 2
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... 3, 2007) Two methods that permit scientists ... in this months release of Cold Spring Harbor ... online ( www.cshprotocols.org ), describe how to fluorescently tag ... combined with sophisticated imaging methods, permit scientists to visualize ...
... with Las Vegas and Tucson Marathon Runners, PLEASANT ... an event to prevent inflammation and pain, but at ... by researchers at,Appalachian State University and Vanderbilt University, published ... taking ibuprofen,before exercise may be unhealthy in the long ...
... to,build on the issue of requiring physicians to ... Management Association,(PCMA) today announced a new round of ... Last year, Dr. Bootman co-chaired an Institute of ... using e-prescribing by,2010 to help reduce the estimated ...
... ... -, JEFFERSON CITY, Mo., ... -,Missouri Military Family Relief Fund, which will help support the needs of,more than ... for the central market area at,TriWest, will present the check to the Adjutant ...
... Dec. 3 Operon,Biotechnologies, Eurofins MWG and Eurofins ... - announced today that they have agreed to ... leader in the competitive,custom oligonucleotide market. With about ... high-throughput production facilities in all major markets (North,America, ...
... retires; Mike Gallagher, President and CEO of ... Dec. 3 AvMed Health Plans said today ... to retire December 31,2007. As a result, Mike ... HealthCare, who already has overall leadership and strategic,responsibilities ...
Cached Medicine News:Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2Health News:MWG and Operon Are Joining Forces 2Health News:AvMed Announces Senior Leadership Changes 2
Inorganic phosphorus (UV method) reagent is for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: